WO2010149280A1 - Inhaler - Google Patents
Inhaler Download PDFInfo
- Publication number
- WO2010149280A1 WO2010149280A1 PCT/EP2010/003522 EP2010003522W WO2010149280A1 WO 2010149280 A1 WO2010149280 A1 WO 2010149280A1 EP 2010003522 W EP2010003522 W EP 2010003522W WO 2010149280 A1 WO2010149280 A1 WO 2010149280A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- inhaler
- chamber
- amino
- aerosol
- add
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61D—VETERINARY INSTRUMENTS, IMPLEMENTS, TOOLS, OR METHODS
- A61D7/00—Devices or methods for introducing solid, liquid, or gaseous remedies or other materials into or onto the bodies of animals
- A61D7/04—Devices for anaesthetising animals by gases or vapours; Inhaling devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
- A61M11/02—Sprayers or atomisers specially adapted for therapeutic purposes operated by air or other gas pressure applied to the liquid or other product to be sprayed or atomised
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0001—Details of inhalators; Constructional features thereof
- A61M15/0013—Details of inhalators; Constructional features thereof with inhalation check valves
- A61M15/0015—Details of inhalators; Constructional features thereof with inhalation check valves located upstream of the dispenser, i.e. not traversed by the product
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
- A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
- A61M15/0033—Details of the piercing or cutting means
- A61M15/0035—Piercing means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0086—Inhalation chambers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/08—Inhaling devices inserted into the nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/0003—Accessories therefor, e.g. sensors, vibrators, negative pressure
- A61M2016/0015—Accessories therefor, e.g. sensors, vibrators, negative pressure inhalation detectors
- A61M2016/0018—Accessories therefor, e.g. sensors, vibrators, negative pressure inhalation detectors electrical
- A61M2016/0024—Accessories therefor, e.g. sensors, vibrators, negative pressure inhalation detectors electrical with an on-off output signal, e.g. from a switch
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/82—Internal energy supply devices
- A61M2205/8275—Mechanical
- A61M2205/8281—Mechanical spring operated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2250/00—Specially adapted for animals
Definitions
- the present invention relates to an inhaler according to the preamble clause of claim 1, 9 or 12.
- the present invention relates in particular to a so-called soft mist inhaler (SMI), i.e. an inhaler that produces a spray mist (aerosol) that spreads out only relatively slowly.
- SMSI soft mist inhaler
- Inhalers of this kind in the sense of the present invention are, in particular, inhalers in which an aerosol is delivered at a speed of less than 2 m/s, preferably about 1.6 m/s or less and most preferably less than 1 m/s (in each case measured at a distance of 10 cm from a expulsion nozzle) and/or wherein the delivery or nebulisation of a dose - of preferably 10 to 50 ⁇ l of a medicament preparation - lasts longer than 0.7 s, particularly about 1 s or longer.
- WO 2005/079997 Al discloses an inhaler which represents an SMI in the sense of the present invention.
- the known inhaler comprises, as the reservoir for a medicament preparation that is to be nebulised, an insertable rigid container having an inner bag containing the medicament preparation and a pres- sure generator with a drive spring for conveying and nebulising the medicament preparation. Nebulisation takes place without the use of propellant gas, namely by the force of the drive spring.
- a problem with inhalers and SMIs in general is that the triggering of the nebu- lisation of the medicament preparation and the intake of breath have to be coordinated. This may be difficult for the individual user. This tends to be a problem with SMIs on account of the relatively long nebulisation time for each dose. Therefore, SMIs have not hitherto been used for people with coordination problems such as small children, or for animals, particularly large animals such as horses.
- WO 2004/091704 Al discloses an add-on device for the intermediate storage of a nebulised medicament preparation in a chamber.
- the add-on device is used in a so-called metered dose inhaler (MDI).
- MDI comprises a pressur- ised container which contains the medicament preparation that is to be nebulised as well as a propellant gas.
- the propellant gas causes the medicament preparation to be dispensed at comparatively high pressure and correspondingly high speed and with a high mass flow. Therefore the delivery takes place over a very short time and lasts in particular for less than 0.4 s, usually for about 0.15 - 0.36 s.
- the short duration of delivery is disadvanta- geous for inhalation as the intake of breath for inhalation normally takes considerably longer.
- the relatively high speed of more than 2 m/s, in many cases up to or over 8 m/s, at which the aerosol is usually delivered by an MDI, is also disadvantageous for inhaling into the lungs as the particles (droplets) of the aerosol are largely deposited on the walls of the user's throat when inhaled directly because of the high speed.
- the known add-on device is intended for an MDI and serves to slow down the aerosol, particularly by increasing the flow distance. For this reason add-on devices of this kind are also known as spacers. Moreover, the add-on device serves for intermediate storage of the aerosol produced.
- WO 01/78818 A2 discloses an inhaler for the nose.
- the inhaler has a manually operable pump bottle and an adapter mounted thereon with a chamber for intermediate storage of an aerosol produced.
- the pump bottle is not an SMI in the sense of the present invention. Rather, the pump bottle has to be operated briefly and forcefully in order to achieve reasonable nebulisation, so that the characteristics correspond to those of a uDI, if indeed the pump bottle is able to produce an aerosol comprising the very small droplets that are desirable for inhalation into the lungs.
- WO 94/17753 Al discloses an inhalation device for large animals such as horses.
- the inhalation device comprises a uDI which delivers an aerosol into an add-on device having a tubular portion.
- the aerosol is sprayed in the longitudinal direction of the tubular portion.
- a soft adaptor which is designed to be introduced into a horse's nostril can be connected to the tubular portion.
- the inhalation device comprises a handle with an associated, manually operated, pivotable trigger element. When the trigger element is operated, the MDI is pushed in a linear manner, thereby opening a metering valve in the MDI and delivering aerosol into the tubular portion.
- a disadvantage of MDIs is that the nebulisation uses propel- lant gas.
- Object of the present invention is to provide an inhaler, most preferably an SMI, by means of which the inhalation even of aerosols delivered at low speed is made easier and/or wherein problems of co-ordinating the intake of breath and the triggering of the inhaler are avoided or at least minimised and/or wherein the inhaler is suitable particularly for use with animals, preferably large animals such as horses, and/or is suitable for more universal use.
- an inhaler most preferably an SMI
- an inhaler particularly in the form of an SMI is combined with an add-on device having a chamber for intermediate storage, i.e. temporary storage, of the aerosol pro- cuted, the chamber being arranged downstream of a expulsion nozzle of the inhaler.
- the proposed solution permits better defined inhalation of the active sub- stance with a fraction of active substance deposited in the lungs that is higher on average and/or fluctuates less than in an MDI. This permits improved treatment or the use of different medicament preparations which have to be metered more accurately. Finally, the SMI is as a result more versatile.
- the aerosol is introduced into the chamber at right angles to a main dispensing direction and/or the longitudinal direction of the chamber. This results in a compact construction and/or enables a conventional inhaler to be used which delivers the aerosol in the longitudinal direction.
- the add-on device comprises an inlet valve for admitting supply air into the chamber and for blocking flow in the opposite direction. This presents the unwanted blowing of the aerosol out of the chamber during an outward breath.
- the inlet valve is arranged upstream of a connector for admitting the aerosol into the chamber. This avoids the aerosol having to flow through the inlet valve and being impeded by it.
- the add-on device has a breath intake indicator for indicating an airflow through the chamber in the dispensing direction.
- a breath intake indicator for indicating an airflow through the chamber in the dispensing direction. This assists with the use of the inhaler or the triggering of the nebulisation, as it thus indicates the intake of breath to the operator or user. This assists with co-ordination and therefore promotes the universal use of the inhaler, for example in people who cannot initiate the nebulisation themselves, or in animals.
- the add-on device comprises a dispensing connector for connecting to a dispensing device only in a defined rotational position.
- the inhaler comprises a trigger element which is arranged on the long side with respect to a main dispensing direction and/or longitudinal extent of the chamber.
- the dispensing device has a larger diameter or cross-section than the chamber.
- additional intermediate storage can be obtained.
- the inhaler comprises means for mechanically cleaning an expulsion nozzle.
- the means comprises in particular a swivel element and/or a cleaning element. This enables the inhaler to be used more universally, for example for animals as well, particularly large animals such as horses, while any contamination of the expulsion nozzle which might have a negative effect on the dosing or nebulisation can be avoided or eliminated by the proposed means.
- the inhaler is constructed to be operated with one hand, in particular to allow one-handed tensioning of a spring or other energy store which brings about the actual nebulisation.
- the nebulisation can then preferably also be triggered one-handedly by an operator, in particular.
- This permits particularly simple handling of the preferably propellant-free inhaler so that it can be used more universally, particularly also for people with co-ordination prob- lems and/or for animals, preferably large animals, especially horses.
- Fig. 1 shows a schematic section through an inhaler in the untensioned state
- Fig. 2 shows a schematic section through the inhaler in the tensioned state, rotated through 90° compared with Fig. 1;
- Fig. 3 shows a schematic view of the inhaler with the add-on device connected
- Fig. 4 shows a schematic section through the inhaler with the add-on device and a dispensing device in the state of attachment to a horse's nostril;
- Fig. 5 shows a side view of the inhaler with the add-on device connected, in a modified embodiment
- Fig. 6 shows a plan view of the inhaler according to Fig. 5.
- Figs. 1 and 2 show a portable inhaler for propellant-free nebulisation of a medicament preparation 2 in schematic view in the untensioned state (Fig. 1) and in the tensioned state (Fig. 2).
- Figs. 1 and 2 show the inhaler 1 with a con- tainer 3 containing the medicament preparation 2.
- an aerosol 14 destined for the lungs is formed (Fig. 1) which can be breathed in or inhaled by a user or patient (not shown) such as an animal, human being or preferably a large animal, particularly a horse.
- a user or patient such as an animal, human being or preferably a large animal, particularly a horse.
- the inhalation takes place at least once a day, more particularly several times a day, preferably at predetermined intervals, depending in particular on the complaint.
- the inhaler 1 is constructed in particular as a soft mist inhaler as described hereinbefore.
- the inhaler 1 comprises the preferably insertable and optionally replaceable container 3 with the medicament preparation 2.
- the container 3 thus forms a reservoir for the medicament preparation 2 that is to be nebulised.
- the container 3 contains a sufficient amount of medicament preparation 2 or active substance for several doses of the medicament preparation 2, i.e. to allow a number of nebulisations or applications.
- the container 3 is preferably substantially cylindrical or cartridge-shaped and after the inhaler 1 has been opened the container can be inserted therein from below and optionally replaced. It is preferably of rigid construction, the medicament preparation 2 being contained in particular in a collapsible bag 4 in the container 3.
- the inhaler 1 also comprises a conveying device or a pressure generator 5, for conveying and nebulising the medicament preparation 2, particularly in a predetermined and optionally adjustable dosage amount in each case, i.e. for me- tered nebulisation or nebulisation in a plurality of defined doses.
- a conveying device or a pressure generator 5 for conveying and nebulising the medicament preparation 2, particularly in a predetermined and optionally adjustable dosage amount in each case, i.e. for me- tered nebulisation or nebulisation in a plurality of defined doses.
- One dose may be administered on each actuation of the inhaler 1.
- the inhaler 1 or pressure generator 5 is particularly designed so that the conveying, pressure generation and/or nebulisation take place without the use of propellants, mechanically and/or by the energy or force of an energy store, particularly a spring store, most preferably by the spring force of a drive spring 7, in the embodiment shown.
- an energy store particularly a spring store, most preferably by the spring force of a drive spring 7, in the embodiment shown.
- other design solutions are also possible.
- the inhaler 1 or pressure generator 5 comprises in particular a holder 6 for the container 3, the associated drive spring 7, which is only partly shown, prefer- ably having an associated trigger element 8 which is manually operable to release it, a conveying element, preferably a conveying tube 9 in the form of a capillary, with an optional valve, particularly a non-return valve 10, a pressure chamber 11 and/or an expulsion nozzle 12, particularly in the region of an out- let or mouthpiece 13.
- the container 3 is fixed in the inhaler 1 by means of the holder 6, particularly by a clamping or latching action, such that the conveying tube 9 protrudes into the container 3.
- the holder 6 may be constructed such that the container 3 can be exchanged.
- the inhaler 1 or pressure generator 5 preferably comprises a tensioning device.
- the drive spring 7 is axially ten- sioned, the holder 6 with the container 3 and the conveying tube 9 is moved downwards in the Figures and the medicament preparation 2 - or more precisely the next dose - is sucked out of the container 3 into the pressure chamber 11 of the pressure generator 5 through the non-return valve 10.
- the medicament preparation 2 in the pressure chamber 11 is placed under pressure by moving the conveying tube 9 back up, with the nonreturn valve 10 now closed, by releasing the tension on the drive spring 7, so that this conveying tube 9 now acts as a pressure ram.
- This pressure expels the medicament preparation 2 through the expulsion nozzle 12, where it is nebulised into the preferably inhalable aerosol 14, as shown in Fig. 1.
- the user or patient can inhale the aerosol 14, while preferably supply air can be sucked into the connector 13 through at least one supply air opening 15.
- the container 3 is moved back into its original position by the drive spring 7.
- the container 3 thus performs a lifting movement during the tensioning process and during the nebulisation process.
- the inhaler 1 comprises in particular a first housing part (upper part) 16 and an inner part 17 which is rotatable relative thereto (Fig. 2) having an upper part 17a and a lower part 17b (Fig. 1), while a second housing part (lower part) 18, which is in particular manually operable or rotatable, is releasably attached, in particular pushed onto the inner part 17, preferably by means of a safety closure or retaining element 19.
- the safety closure or re- taining element 19 is constructed such that accidental opening of the inhaler 1 or removal of the second housing part 18 is prevented.
- the retaining element 19 has to be pressed in against spring force.
- the second housing part 18 can be detached from the inhaler 1.
- the second housing part 18 preferably forms a cap-like lower housing part and/or engages around or over a lower free end portion of the container 3.
- the second housing part 18 can be rotated relative to the first housing part 16, whereby the inner part 17 is also rotated.
- the drive spring 7 is ten- sioned in the axial direction by means of a gear (not shown in detail) acting on the holder 6, which acts in particular via a screw thread on the holder 6 or indirectly or directly.
- a gear not shown in detail
- the container 3 is moved axially downwards or with its end portion (further) into the second housing part 18 or towards the end face thereof, until the container 3 assumes an end position shown in Fig. 2. In this state the drive spring 7 or inhaler 1 is clamped and locked.
- the tensioning device for tensioning the drive spring 7 or other energy or spring store comprises, in particular, at least one rotatable part, such as the second housing part 18 and/or inner part 17 and in this case preferably also the gear for converting the rotary movement into the linear, in this case axial, tensioning movement.
- the rotary movement is always continued in the same direction of rotation during tensioning; therefore, reverse rotation is not required.
- other design solutions are also possible.
- the inhaler 1 preferably has a device for forcibly ventilating the container 3.
- the container 3 When tensioning first takes place, the container 3 is preferably pierced in its base or opened.
- an axially acting spring 20 arranged in the housing part 18 comes to abut on the container base 21 and with a piercing element 22 pierces the container 3 or an in particular gastight seal provided in the base for ventilation purposes when contact is first made.
- the device for forcible ventilation is thus formed in this case by the piercing element 22, which is held or formed by the spring 20.
- the piercing element 22 which is held or formed by the spring 20.
- other design solutions are also possible.
- the container 3 In order to use the inhaler 1, first of all the container 3 has to be inserted. This is preferably done by removing or pulling out the second housing part 18. The container 3 is then axially inserted or pushed into the inner part 17. At the same time the container 3 is opened at the head end or attached. This is done by means of the conveying element, i.e. the conveying tube 9, which pierces a seal preferably provided at the head end of the container 3 and is then inserted through a septum at the head end of the container 3 into the interior of the bag 4.
- the conveying element i.e. the conveying tube 9
- the conveying tube 9 which pierces a seal preferably provided at the head end of the container 3 and is then inserted through a septum at the head end of the container 3 into the interior of the bag 4.
- the second housing part 18 is pushed on again.
- the inhaler 1 can now be tensioned for the first time.
- the container 3 is then pierced at its base by the piercing element 22, i.e. forcibly ventilated, as explained previously.
- the inhaler 1 is preferably tensioned and triggered several times. This so-called priming displaces any air present in the medicament preparation 2 in the conveying tube 9 and in the pressure generator 5 to the expulsion nozzle 12. The inhaler 1 is then ready for inhalation.
- the quantity of medicament preparation 2 delivered per spray or nebulisation process is preferably about 10 ⁇ l to 50 ⁇ l, more particularly about 10 ⁇ l to 20 ⁇ l, most preferably about 15 ⁇ l.
- the drive spring 7 is preferably installed in a biased state in order to achieve a high spring pressure.
- the pressurisation and conveying of the medicament preparation 2 during the nebulisation process takes place preferably only by spring force, and more particularly only by the force of the drive spring 7.
- the inhaler 1 is preferably constructed such that the medicament preparation 2 in the pressure generator 5 or in the pressure chamber 11 reaches a pressure of 5 MPa to 60 MPa, particularly about 10 MPa to 50 MPa during delivery. Particularly preferably, during the delivery or nebulisation of the medicament preparation 2, a pressure of about 5 MPa to 60 MPa, more particularly about 10 to 30 MPa, is reached at the expulsion nozzle 12 or at the nozzle openings thereof.
- the medicament preparation 2 is then converted into the aerosol 14, the droplets of which have an aerodynamic diameter of up to 20 ⁇ m, preferably about 3 ⁇ m to 10 ⁇ m.
- the nebulising activity or nebulising effect is achieved or further assisted by preferably intercepting jets delivered by the expulsion nozzle 12.
- the inhaler 1 is preferably constructed such that the aerosol 14 is delivered at low speed, particularly at a speed of less than 2 m/s, most preferably about 1.6 m/s or less (in each case measured at a distance of 10 cm from the expulsion nozzle 12).
- the inhaler 1 is thus preferably in the form of an SMI.
- the low dispensing speed can be obtained or assisted by intercepting jets of the medicament preparation 2, which are delivered by the expulsion nozzle 12 and/or by a suitable choice of spring force.
- the construction of the inhaler 1 is such that the aerosol generation lasts for more than 0.7 s, preferably substantially 1 s or longer, in particular for more than 1.5 s.
- the time taken to nebulise a dose or to actuate the inhaler 1 is thus preferably more than 0.75, more particularly about 1 s or more.
- the inhaler 1 preferably has an add-on device 23 with a chamber 24 for receiving and/or intermediately storing the aerosol 14 produced by the inhaler 1, as is shown in a schematic section according to Fig. 4.
- the chamber 24 is arranged or adapted to be arranged downstream of the expulsion nozzle 12. It serves to receive and/or intermediately store the aerosol 14 produced by the inhaler 1.
- the add-on device 23 or its chamber 24 is at least substantially tubular, cylindrical, elongate or conical in construction.
- the add-on device 23 preferably comprises a connector 25 for mechanical and/or fluidic connection to the inhaler 1 or its connecting member 13.
- the add-on device 23 is releasably or non-releasably connectable to the inhaler 1 or connecting member 13, for example by pushing on, clamping on or latching.
- the aerosol 14 is introduced into the chamber 24 at right angles or perpendicularly to a longitudinal dimension or main dispensing direction in the chamber 24.
- Fig. 4 schematically shows how the aerosol 14 is delivered from the inhaler 1 through the lateral connector 25 into the chamber 24.
- the inhaler 1 or add-on device 23 preferably comprises a dispensing device 27, such as an adapter, that can be attached at the outlet end.
- the add-on device 23 preferably comprises at the outlet end a dispensing connector 26 particularly for connecting to the associated dispensing device 27, as schematically shown in Fig. 4.
- the add-on device 23 or chamber 24 preferably has an inlet opening 28 for admitting supply air (ambient air).
- the inlet opening 28 is preferably provided on the end of the add-on device 23 or chamber 24 opposite the dispensing connector 26, and/or upstream of the connector 25.
- other arrangements are also possible.
- the connector 25 for connecting to the inhaler 1 or for admitting the aerosol 14 produced by the inhaler is preferably arranged between the two ends of the add-on device 23 or chamber 24 or between the dispensing connector 26 and the inlet opening 28.
- the inhaler 1 is arranged on the side of the add-on device 23 or chamber 24 or extends at right-angles or perpendicularly to the longitudinal direction or main dispensing direction thereof.
- other geometric arrangements are also possible.
- the chamber 24 is of larger cross section than the connecting member 13 and/or widens out at least in parts towards a delivery end or connector or free end of the add-on device 23. This ensures that the aerosol 14 strikes a wall of the chamber 24 over the smallest possible area. In this way it is possible to minimise the deposition or settling of the nebulised medicament preparation 2 on the wall of the chamber.
- the add-on device 23 or chamber 24 comprises an inlet valve 29 for admitting supply air into the chamber 24, the inlet valve 29 preferably blocking or throttling the flow in the opposite direction, in particular so that during an outward breath, air cannot escape from the chamber 24 through the inlet opening 28 and pass into the atmosphere.
- the inlet valve 29 is preferably in the form of a non-return valve or clack-type valve, which may or may not be biased into the closed position.
- other design solutions are also possible.
- the optional supply air openings 15 are closed or provided with an associated sup- ply air valve, so that no air can be released from the chamber 24 through the connector 25 and the supply air opening(s) 15.
- the inhaler 1 or the add-on device 23 preferably comprises a breath intake indicator 30 for indicating a flow of air particularly in the chamber 24 in the dispensing direction.
- the breath intake indicator 30 thus indicates in particular when the patient breathes in or inhales, in particular when air flows from the inlet opening 28 through the chamber 24 to the dispensing connector 26.
- the breath intake indicator 30 preferably comprises a pivotably mounted part that is leaf-shaped, in particular, and/or can be de- fleeted or pivoted by the flow of air.
- other design solutions are also possible.
- the add-on device 23 or its housing or the walls of the chamber 24 are transparent at least in parts or completely transparent, in order that the breath intake indicator 30 can be seen from outside and/or so that any con- tamination or the like can be detected from outside.
- the chamber 24 is larger in diameter or cross-section than the connecting member 13, particularly by a factor of 1.5 or more, most preferably by a factor of 2 or more. This reduces the tendency of the aerosol 14 to be depos- ited on the walls of the chamber 24.
- the chamber 24 preferably has a volume of more than 0.1 1, particularly more than 0.2 1, most preferably about 0.2 to 0.6 1.
- the add-on device 23 or the size of the chamber 24 is adapted to the inhaler 1 such that the aero- sol 14 produced on actuation of the inhaler 1 can be at least substantially entirely received by the chamber 24 in particular without the aerosol 14 or the nebulised medicament preparation 2 essentially being deposited or settling on the inner wall of the chamber.
- the add-on device 23 is preferably at least substantially rigid in construction.
- the add-on device 23, the chamber 24 or its housing may theoretically also be flexible, inflatable and/or telescopic in construction, in order to minimise the space taken up when not in use and/or for transportation purposes, in particular.
- the add-on device 23 is preferably not rotatable relative to the inhaler 1. In the embodiment shown this is achieved by the fact that the connecting member 13 of the inhaler 1 has a non-round but preferably oval outer contour to which the connector 25 is adapted accordingly. However, other design solu- tions are also possible.
- the dispensing connector 26 is preferably constructed so that the dispensing device 27 can only be connected to the add-on device 23 in a defined rotational position.
- the dispensing connector 26 comprises for this purpose at least one axial slot or the like, as schematically shown in Fig. 3, into which the dispensing device 27 can engage by means of a rib, a projection or a strut, for example.
- a rib a projection or a strut
- the dispensing device 27 can be connected to the add-on device 23 by latching and/or clamping and/or by a bayonet connection or the like.
- latching and/or clamping and/or by a bayonet connection or the like can be connected to the add-on device 23 by latching and/or clamping and/or by a bayonet connection or the like.
- other design solutions are also possible.
- the dispensing device 27 may also be irremovably connected or connectable to the add-on device 23 or formed in one piece therewith or formed thereby .
- the dispensing device 27 preferably has a larger diameter or cross-section than the chamber 24, as indicated in Fig. 4.
- the dispensing device 27 preferably has a soft end piece or forms such an end piece.
- the dispensing device 27 is preferably constructed as a nasal adapter for insertion in a nostril 31 of a horse 32 or other animal, particularly a large ani- mal, as schematically shown in Fig. 4.
- the inhaler 1 or the addon device 23 or the dispensing device 27 is thus designed so that the aerosol 14 is prepared for inhalation by the horse 32 or other animal or large animal.
- the dispensing device 27 is designed to be inserted in the left nostril 31 of the horse 32.
- the dispensing device 27 preferably comprises an outlet 33, that engages or can be inserted in the nostril 31 or a nasal passage 34 of the horse 32.
- the connecting device 27 is designed so that the outlet 33 al- ways goes in the correct nasal passage 34 and does not end in a blind passage 35.
- the connecting device 27 is constructed as described in WO 94/17753 Al .
- the inhaler 1 is preferably connected or connectable to the add-on device 23 such that the trigger element 8 is arranged laterally, and in the representation shown in Fig. 4 on the side facing the observer and/or on the side towards which the outlet 33 opens.
- the trigger element 8 is arranged so that the inlet opening 28 is to the left of it and/or the dispensing connector 26 is to the right of it.
- the preferred arrangement described above makes it possible or easier for an operator (not shown) to stand to the left next to the neck or head of the horse 32 (part of the head with the nostril 31 is shown schematically in section in Fig. 4), while the operator may position himself to look straight ahead in the direction of travel of the horse 32, can hold the horse 32 with his right hand on its neck or head, particularly using a halter or the like (not shown), and with his left hand can hold the inhaler 1 in the position shown in Fig. 4 with the dispensing device 27 inserted in the nostril 31, using the thumb of his left hand, in particular, to operate the trigger element 8 for actuating the inhaler 1, i.e. for initiating a nebulisation.
- the operation of the inhaler 1 is made even easier if it is constructed so that it can be tensioned and triggered with one hand. In particular it is then possible for a single operator to hold both the inhaler 1 and the horse 32 or other animal at the same time and perform a number of actuations (i.e. tensioning and triggering for one actuation in each case) with one hand. Accordingly he does not have to let go of the horse 32.
- the inhaler 1 or its dispensing device 27 can be held continuously in fluidic connection with the horse 32 or animal during the nebulisation of a number of doses.
- the inhaler 1 preferably comprises means 36 for covering and/or cleaning the expulsion nozzle 12, as schematically shown in Fig. 4.
- any soiling of the expulsion nozzle 12 which might interfere with good nebulisation and/or dosing can be prevented and/or eliminated. Such soiling may easily occur in particular in a rougher environment, such as in a stable or the like.
- the means can preferably be operated from outside.
- the means are constructed as a swivel element 36 or designed to be pivotable. However, they may also consist of a slide, carriage or the like.
- the means preferably comprise a cleaning element 37, for example in the form of a sponge, a brush or the like.
- a cleaning element 37 for example in the form of a sponge, a brush or the like.
- other design solutions are also possible here.
- the means can be used for example to cover the expulsion nozzle 12 before any cleaning of the add-on device 23 or chamber 24.
- the expulsion nozzle 12 can be cleaned for example after the cleaning of the add-on device 23 or chamber 24 and/or after removal of the add-on device 23 using the means or cleaning element 37.
- the inhaler 1 is connected or connectable to the add-on device 23 such that the inhaler 1 or its housing (formed in this case from the two hous- ing parts 16 and 18) is not movable or slidable relative to the add-on device 23 or dispensing device 27 during actuation or use.
- the inhaler 1 or its housing formed in this case from the two hous- ing parts 16 and 18
- the inhaler 1 or its housing comprises a grip or handle for holding the add-on device 23 and/or dispensing device 27 during use.
- a grip or handle for holding the add-on device 23 and/or dispensing device 27 during use.
- Fig. 5 shows a side view
- Fig. 6 a plan view.
- the inhaler 1 is designed to be tensioned and released using one hand.
- a tensioning device 38 is associated with the inhaler 1.
- the construction in which the inhaler 1 can be tensioned and released using one hand can also be achieved independently of other aspects, in particular also independently of the add-on device 23 and/or dispensing device 27.
- the tensioning device 38 preferably also comprises a rotatable part, particularly the inner part 17 of the inhaler 1, for tensioning the drive spring 7 or other spring store or energy store.
- the tensioning device 38 preferably comprises a manually operable actuating element 39 which is preferably pivotable on actuation, in particular counter to the force of an associated restoring spring 40.
- the ac- tuating element 39 is pivotably held on the inhaler 1 or its housing and/or by the add-on device 23.
- the tensioning device 38 comprises an in particular housing-like receptacle 41, in particular in the form of an over- housing, for the inhaler 1, as shown in Fig. 5.
- the inhaler 1 can be inserted in the receptacle 41, in particular so that the trigger element 8 can still be actu- ated from outside - for example through an opening in the receptacle 41 - and/or so as to enable tensioning of the drive spring 7, particularly by operation of the actuating element 39.
- the tensioning device 38 comprises a holding por- tion or grip member 42, which is formed in this case particularly by the outside of the receptacle 41.
- the inhaler 1 is thus preferably arranged in the grip member 42 or can be accommodated therein.
- the grip member 42 may also be constructed separately or as a separate part.
- the tensioning device 38 preferably comprises a coupling element 43, for converting the movement of the actuating element 39 on actuation into a driving movement - in this case for rotating the housing part 18 and/or part 17 or a gear or the like for tensioning the drive spring.
- the pivoting movement of the actuating element 39 is converted into a linear movement.
- the coupling element 43 is preferably constructed as a toothed rack which preferably engages by means of corresponding teeth in external teeth, in particular, provided on the housing part 18 or inner part 17.
- a flexible coupling element may also be provided, which is guided for example around the housing of the inhaler 1 or the housing part 18 or inner part 17, so as to allow a particularly compact construction.
- the tensioning device 38 preferably forms a construction unit which accommodates and/or holds the inhaler 1 and which preferably also holds the add-on device 23 and/or connecting device 27.
- the inhaler 1 preferably also holds the add-on device 23 and/or connecting device 27.
- other design solutions are also possible.
- the actuating element 39 is manually operated, preferably pivoted, in this case towards the grip member 42.
- the coupling element 43 converts this pivoting movement into a linear movement in the embodiment shown.
- the coupling element 43 is guided on the receptacle 41 or on the grip member 42 in particular to be movable only in a linear manner - for example in the manner of a slide - and is coupled to the free end of the actuating element 39 in particular via an oblong hole.
- other design solutions are also possible here.
- the linear movement of the coupling element 43 during the tensioning of the inhaler 1 preferably runs from left to right, in the view shown in Fig. 5.
- the linear movement causes the part 17 and/or 18 to rotate and the drive spring 7 to be tensioned.
- the nebulisation may be activated.
- this is done by pressing the trigger element 8, which releases the holder 6 or drive spring 7, so that the force of the drive spring 7 causes the dose of medicament preparation 2 contained in the pressure chamber 11 to be nebulised through the expulsion nozzle 12 - and in particular into the add-on device 23 attached thereto.
- the operation is triggered in particular when the breath in- take indicator 30 shows an intake of breath, i.e. a flow of air in the direction of the dotted arrow shown in Fig. 4. It should be noted that in Fig. 4 the breath indicator 30 is shown in the resting position. The flow of air would cause the preferably leaf-like element to be deflected to the right, for example.
- the longitudinal extent or main delivery direction of the add-on device 23 or chamber 24 preferably runs in the direction of the dotted arrow.
- the longitudinal extent of the inhaler 1 and/or the pivot axis of the actuating element 39 preferably extends at right angles or perpendicularly thereto.
- the pivot axis of the actuating element 39 preferably extends substantially parallel thereto.
- the actuating element 39 is arranged on the side of the inhaler 1 or receptacle 41 or grip member 42 which is remote from the trigger element 8.
- the actuating element 39 can be pulled towards the grip member 42 and towards an operator, who, as already explained, is preferably standing at right angles to the main dispensing direction or longitudinal direc- tion of the add-on device 23 or chamber 24, most preferably on the right-hand side of the inhaler 1.
- the direction of actuation of the tensioning device 38 or of the actuating element 39 preferably runs counter to the direction of actuation of the trigger element 8 and/or at right-angles or perpendicularly to the main dispensing direction or longitudinal direction of the add-on device 23 or chamber 24.
- actuating element 39 when operated the actuating element 39 can also perform a different movement, i.e. some other movement, i.e. an additional movement or linear movement.
- the coupling element 43 may also be omitted and the actuating element 39 may for example act directly on the part 17 or 18 or on some other gear part of the inhaler 1.
- Fig. 5 schematically shows a slot 44 for the means (not shown) for covering or cleaning.
- the means may be constructed as a slide which is guided for example by the add-on device 23, allows the connector 25 or con- necting member 25 to be covered, and/or is operable from outside.
- the grip 42 is preferably formed pistol-like. This applies for all embodiments.
- the inhaler 1 can be operated multiple times with one operation after the other, in particular without changing container 3 or refilling the inhaler 1.
- the inhaler 1 contains multiple doses of the medicament 2. This applies for all embodiments.
- the proposed inhaler 1 is designed in particular for the brief nebulisation of the medicament preparation 2, for example for only one or two breaths. However, it may also be designed or usable for longer or continuous nebulisation.
- the proposed inhaler 1 makes it possible in particular for a plurality of doses to be nebulised and dispensed one after another. This may be done by one- handed operation, in particular. Thus, an operator has the other hand free for holding a person requiring assistance, such as a small child or older person, or an animal such as a horse or the like. This allows particularly universal application.
- W is a pharmacologically active substance and is selected (for example) from among the betamimetics, anticholinergics, corticosteroids, PDE4-inhibitors, LTD4-antagonists, EGFR-inhibitors, dopamine agonists, Hl -antihistamines, PAF-antagonists and PI3 -kinase inhibitors.
- double or triple combi- nations of W may be combined and used in the device according to the invention.
- Combinations of W might be, for example: - W denotes a betamimetic, combined with an anticholinergic, corticosteroid, PDE4-inhibitor, EGFR-inhibitor or LTD4-antagonist,
- - W denotes an anticholinergic, combined with a betamimetic, corticosteroid, PDE4-inhibitor, EGFR-inhibitor or LTD4-antagonist
- - W denotes a corticosteroid, combined with a PDE4-inhibitor, EGFR- inhibitor or LTD4-antagonist
- - W denotes a PDE4-inhibitor, combined with an EGFR-inhibitor or LTD4- antagonist
- - W denotes an EGFR-inhibitor, combined with an LTD4-antagonist.
- the compounds used as betamimetics are preferably compounds selected from among albuterol, arformoterol, bambuterol, bitolterol, broxaterol, car- buterol, clenbuterol, fenoterol, formoterol, hexoprenaline, ibuterol, isoetharine, isoprenaline, levosalbutamol, mabuterol, meluadrine, meta- proterenol, orciprenaline, pirbuterol, procaterol, reproterol, rimiterol, ri- todrine, salmefamol, salmeterol, soterenol, sulphonterol, terbutaline, tiara- mide, tolubuterol, zinterol, CHF-1035, HOKU-81, KUL-1248 and
- the acid addition salts of the betamimetics are preferably selected from among the hydrochloride, hydrobromide, hydriodide, hydrosulphate, hydrophosphate, hydro- methanesulphonate, hydronitrate, hydromaleate, hydroacetate, hydrocitrate, hydrofumarate, hydrotartrate, hydroxalate, hydrosuccinate, hydrobenzoate and hydro-p-toluenesulphonate.
- the anticholinergics used are preferably compounds selected from among the tiotropium salts, preferably the bromide salt, oxitropium salts, preferably the bromide salt, fiutropium salts, preferably the bromide salt, ipratropium salts, preferably the bromide salt, glycopyrronium salts, preferably the bromide salt, trospium salts, preferably the chloride salt, tolterodine.
- the cations are the pharmacologically active constituents.
- the above-mentioned salts may preferably contain the chloride, bro- mide, iodide, sulphate, phosphate, methanesulphonate, nitrate, maleate, acetate, citrate, fumarate, tartrate, oxalate, succinate, benzoate or p- toluenesulphonate, while chloride, bromide, iodide, sulphate, methanesulphonate or p-toluenesulphonate are preferred as counter-ions.
- the chlorides, bromides, iodides and methanesulphonates are particularly pre- ferred.
- Other preferred anticholinergics are selected from among the salts of formula AC-I
- X ⁇ denotes an anion with a single negative charge, preferably an anion selected from among the fluoride, chloride, bromide, iodide, sulphate, phosphate, methanesulphonate, nitrate, maleate, acetate, citrate, fumarate, tartrate, oxalate, succinate, benzoate and p-toluenesulphonate, preferably an anion with a single negative charge, particularly preferably an anion selected from among the fluoride, chloride, bromide, methanesulphonate and p- toluenesulphonate, particularly preferably bromide, optionally in the form of the racemates, enantiomers or hydrates thereof.
- those pharmaceutical combinations which contain the enantiomers of formula AC-I -en
- X ⁇ may have the above-mentioned meanings.
- Other preferred anticholinergics are selected from the salts of formula AC-2
- AC-2 wherein R denotes either methyl or ethyl and wherein X ⁇ may have the above-mentioned meanings.
- the compound of formula AC-2 may also be present in the form of the free base AC-2-base.
- tropenol 2,2-diphenylpropionate methobromide scopine 2,2-diphenylpropionate methobromide, - scopine 2-fluoro-2,2-diphenylacetate methobromide, tropenol 2-fluoro-2,2-diphenylacetate methobromide
- tropenol 3,3',4,4'-tetrafiuorobenzilate methobromide scopine S ⁇ 'A ⁇ -tetrafiuorobenzilate methobromide
- tropenol 4,4'-difluorobenzilate methobromide tropenol 4,4'-difluorobenzilate methobromide, - scopine 4,4'-difluorobenzilate methobromide
- tropenol 3,3'-difluorobenzilate methobromide scopine 3,3'- difluorobenzilate methobromide
- tropenol 9-hydroxy-xanthene-9-carboxylate methobromide scopine 9-hydroxy-xanthene-9-carboxylate methobromide; tropenol 9-methyl-xanthene-9-carboxylate methobromide; scopine 9-methyl-xanthene-9-carboxylate methobromide; tropenol 9-ethyl-xanthene-9-carboxylate methobromide; - tropenol 9-difluoromethyl-xanthene-9-carboxylate methobromide; scopine 9-hydroxymethyl-xanthene-9-carboxylate methobromide,
- corticosteroids it is preferable to use compounds selected from among be- clomethasone, betamethasone, budesonide, butixocort, ciclesonide, deflaza- cort, dexamethasone, etiprednol, flunisolide, fluticasone, loteprednol, mometasone, prednisolone, prednisone, rofleponide, triamcinolone, RPR- 106541, NS-126, ST-26 and
- Any reference to steroids includes a reference to any salts or derivatives, hydrates or solvates thereof which may exist.
- Examples of possible salts and derivatives of the steroids may be: alkali metal salts, such as for example sodium or potassium salts, sulphobenzoates, phosphates, isoni- cotinates, acetates, dichloroacetates, propionates, dihydrogen phosphates, palmitates, pivalates or furoates.
- alkali metal salts such as for example sodium or potassium salts, sulphobenzoates, phosphates, isoni- cotinates, acetates, dichloroacetates, propionates, dihydrogen phosphates, palmitates, pivalates or furoates.
- PDE4-inhibitors which may be used are preferably compounds selected from among enprofyllin, theophyllin, rofiumilast, ariflo (cilomilast), tofimilast, pumafentrin, lirimilast, arofyllin, atizoram, D-4418, Bay- 198004, BY343, CP-
- the acid addition salts of the betamimetics are preferably selected from among the hydrochloride, hydrobromide, hydriodide, hydrosulphate, hydrophosphate, hydromethanesulphonate, hydronitrate, hydromaleate, hydroacetate, hy- drocitrate, hydrofumarate, hydrotartrate, hydroxalate, hydrosuccinate, hydro- benzoate and hydro-p-toluenesulphonate.
- the LTD4-antagonists used are preferably compounds selected from among montelukast, pranlukast, zafirlukast, MCC-847 (ZD-3523), MN-001, MEN- 91507 (LM-1507), VUF-5078, VUF-K-8707, L-733321 and - l-(((R)-(3-(2-(6,7-difluoro-2-quinolinyl)ethenyl)phenyl)-3-(2-(2- hydroxy- 2-propyl)phenyl)thio)methylcyclopropane-acetic acid,
- the acid addition salts of the betamimetics are preferably selected from among the hydrochloride, hydrobromide, hydriodide, hydrosulphate, hydrophosphate, hy- dromethanesulphonate, hydronitrate, hydromaleate, hydroacetate, hy- drocitrate, hydrofumarate, hydrotartrate, hydroxalate, hydrosuccinate, hydro- benzoate and hydro-p-toluenesulphonate.
- salts or derivatives which the LTD4-antagonists may optionally be capable of forming are meant, for example: alkali metal salts, such as for example sodium or potassium salts, alkaline earth metal salts, sulphobenzoates, phosphates, isonicotinates, acetates, propionates, dihydrogen phosphates, palmitates, pivalates or furoates.
- alkali metal salts such as for example sodium or potassium salts, alkaline earth metal salts, sulphobenzoates, phosphates, isonicotinates, acetates, propionates, dihydrogen phosphates, palmitates, pivalates or furoates.
- EGFR-inhibitors which may be used are preferably compounds selected from among cetuximab, trastuzumab, ABX-EGF, Mab ICR-62 and
- the acid addi- tion salts of the betamimetics are preferably selected from among the hydrochloride, hydrobromide, hydriodide, hydrosulphate, hydrophosphate, hydro- methanesulphonate, hydronitrate, hydromaleate, hydroacetate, hydrocitrate, hydrofumarate, hydrotartrate, hydroxalate, hydrosuccinate, hydrobenzoate and hydro-p-toluenesulphonate.
- the dopamine agonists used are preferably compounds selected from among bromocriptin, cabergoline, alpha-dihydroergocryptine, lisuride, pergolide, pramipexol, roxindol, ropinirol, talipexol, tergurid and viozan, optionally in the form of the racemates, enantiomers, diastereomers thereof and optionally in the form of the pharmacologically acceptable acid addition salts, solvates or hydrates thereof.
- the acid addition salts of the betamimetics are preferably selected from among the hydrochloride, hydro- bromide, hydriodide, hydrosulphate, hydrophosphate, hydromethanesulpho- nate, hydronitrate, hydromaleate, hydroacetate, hydrocitrate, hydrofumarate, hydrotartrate, hydrooxalate, hydrosuccinate, hydrobenzoate and hydro-p- toluenesulphonate .
- Hl -Antihistamines which may be used are preferably compounds selected from among epinastine, cetirizine, azelastine, fexofenadine, levocabastine, loratadine, mizolastine, ketotifen, emedastine, dimetindene, clemastine, bami- pine, cexchlorpheniramine, pheniramine, doxylamine, chlorophenoxamine, dimenhydrinate, diphenhydramine, promethazine, ebastine, desloratidine and meclozine, optionally in the form of the racemates, enantiomers, diastereomers thereof and optionally in the form of the pharmacologically accept- able acid addition salts, solvates or hydrates thereof.
- the acid addition salts of the betamimetics are preferably selected from among the hydrochloride, hydrobromide, hydriodide, hydrosulphate, hydro- phosphate, hydromethanesulphonate, hydronitrate, hydromaleate, hydroacet- ate, hydrocitrate, hydrofumarate, hydrotartrate, hydroxalate, hydrosuccinate, hydrobenzoate and hydro-p-toluenesulphonate.
- inhalable macromolecules as disclosed in EP 1 003 478 Al or CA 2297174 Al may also be used.
- the compound may be selected from among the ergot alkaloid de- rivatives, the triptans, the CGRP-inhibitors, the phosphodiesterase-V inhibitors, optionally in the form of the racemates, enantiomers or diastereomers thereof, optionally in the form of the pharmacologically acceptable acid addition salts, the solvates and/or hydrates thereof.
- Examples of ergot alkaloid derivatives are dihydroergotamine and ergotamine.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Anesthesiology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Containers And Packaging Bodies Having A Special Means To Remove Contents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Priority Applications (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK10727359.1T DK2445558T3 (en) | 2009-06-25 | 2010-06-14 | inhaler |
AU2010265187A AU2010265187B2 (en) | 2009-06-25 | 2010-06-14 | Inhaler |
SG2011095320A SG176961A1 (en) | 2009-06-25 | 2010-06-14 | Inhaler |
US13/322,249 US9084660B2 (en) | 2009-06-25 | 2010-06-14 | Inhaler |
JP2012516549A JP2012530567A (en) | 2009-06-25 | 2010-06-14 | Inhaler |
BRPI1011813-6A BRPI1011813B1 (en) | 2009-06-25 | 2010-06-14 | INHALER |
NZ596456A NZ596456A (en) | 2009-06-25 | 2010-06-14 | Inhaler |
ES10727359.1T ES2593428T3 (en) | 2009-06-25 | 2010-06-14 | Inhaler |
CA2764469A CA2764469C (en) | 2009-06-25 | 2010-06-14 | Inhaler |
EP10727359.1A EP2445558B1 (en) | 2009-06-25 | 2010-06-14 | Inhaler |
CN2010800286530A CN102458541A (en) | 2009-06-25 | 2010-06-14 | Inhaler |
MX2011013077A MX2011013077A (en) | 2009-06-25 | 2010-06-14 | Inhaler. |
ZA2011/08257A ZA201108257B (en) | 2009-06-25 | 2011-11-10 | Inhaler |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09008341.1 | 2009-06-25 | ||
EP09008341 | 2009-06-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2010149280A1 true WO2010149280A1 (en) | 2010-12-29 |
Family
ID=42727644
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2010/003522 WO2010149280A1 (en) | 2009-06-25 | 2010-06-14 | Inhaler |
Country Status (19)
Country | Link |
---|---|
US (1) | US9084660B2 (en) |
EP (1) | EP2445558B1 (en) |
JP (2) | JP2012530567A (en) |
KR (1) | KR101641520B1 (en) |
CN (2) | CN102458541A (en) |
AR (1) | AR077248A1 (en) |
AU (1) | AU2010265187B2 (en) |
BR (1) | BRPI1011813B1 (en) |
CA (1) | CA2764469C (en) |
CL (1) | CL2011003298A1 (en) |
CO (1) | CO6480981A2 (en) |
DK (1) | DK2445558T3 (en) |
ES (1) | ES2593428T3 (en) |
MX (1) | MX2011013077A (en) |
NZ (1) | NZ596456A (en) |
SG (1) | SG176961A1 (en) |
TW (1) | TWI526198B (en) |
WO (1) | WO2010149280A1 (en) |
ZA (1) | ZA201108257B (en) |
Cited By (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104001248A (en) * | 2014-06-11 | 2014-08-27 | 邵俊夫 | Essential oil smelling apparatus |
DE202014006617U1 (en) | 2013-08-20 | 2014-11-24 | Boehringer Ingelheim Vetmedica Gmbh | inhaler |
DE202014006619U1 (en) | 2013-08-20 | 2014-11-24 | Boehringer Ingelheim Vetmedica Gmbh | inhaler |
DE202014006618U1 (en) | 2013-08-20 | 2014-11-24 | Boehringer Ingelheim Vetmedica Gmbh | inhaler |
WO2015024651A1 (en) | 2013-08-20 | 2015-02-26 | Boehringer Ingelheim Vetmedica Gmbh | Inhaler |
WO2015024653A1 (en) | 2013-08-20 | 2015-02-26 | Boehringer Ingelheim Vetmedica Gmbh | Inhaler |
WO2015024652A1 (en) | 2013-08-20 | 2015-02-26 | Boehringer Ingelheim Vetmedica Gmbh | Inhaler |
US20150174343A1 (en) * | 2012-03-09 | 2015-06-25 | Vectura Gmbh | Mixing channel for an inhalation device and inhalation device |
US9179691B2 (en) | 2007-12-14 | 2015-11-10 | Aerodesigns, Inc. | Delivering aerosolizable food products |
WO2015193213A1 (en) * | 2014-06-18 | 2015-12-23 | Boehringer Ingelheim Vetmedica Gmbh | Muscarinic antagonists and combinations thereof for the treatment of airway disease in horses |
EP3257542A1 (en) * | 2013-08-09 | 2017-12-20 | Boehringer Ingelheim International GmbH | Nebulizer |
EP3272381A1 (en) * | 2016-07-22 | 2018-01-24 | La Diffusion Technique Francaise | Inhaler device and treatment system |
US9918995B2 (en) | 2012-12-21 | 2018-03-20 | Boehringer Ingelheim Vetmedica Gmbh | Ciclesonide for the treatment of airway disease in horses |
US9943654B2 (en) | 2010-06-24 | 2018-04-17 | Boehringer Ingelheim International Gmbh | Nebulizer |
US10016568B2 (en) | 2009-11-25 | 2018-07-10 | Boehringer Ingelheim International Gmbh | Nebulizer |
US10124129B2 (en) | 2008-01-02 | 2018-11-13 | Boehringer Ingelheim International Gmbh | Dispensing device, storage device and method for dispensing a formulation |
US10124125B2 (en) | 2009-11-25 | 2018-11-13 | Boehringer Ingelheim International Gmbh | Nebulizer |
US10220163B2 (en) | 2012-04-13 | 2019-03-05 | Boehringer Ingelheim International Gmbh | Nebuliser with coding means |
WO2019125304A1 (en) * | 2017-12-18 | 2019-06-27 | National University Of Singapore | Spacer device for an inhaler and method of manufacture thereof |
WO2019178693A1 (en) * | 2018-03-21 | 2019-09-26 | Protecsom Amerique Du Nord Inc. | Nasal cannula for an aerosol reservoir such as an inhalation chamber |
EP3632373A1 (en) | 2013-08-20 | 2020-04-08 | Boehringer Ingelheim Vetmedica GmbH | Inhaler |
US10925964B2 (en) | 2012-12-21 | 2021-02-23 | Boehringer Ingelheim Vetmedica Gmbh | Pharmaceutical formulation comprising ciclesonide |
EP4124251A4 (en) * | 2021-06-08 | 2023-10-25 | KT&G Corporation | Aerosol generation device |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0913488D0 (en) * | 2009-08-01 | 2009-09-16 | Reckitt Benckiser Nv | Product |
US20110303218A1 (en) * | 2010-06-09 | 2011-12-15 | Yadidi Kambiz | Nasal nebulizer |
GB201101006D0 (en) | 2011-01-21 | 2011-03-09 | Reckitt Benckiser Nv | Product |
US9433736B2 (en) * | 2013-07-03 | 2016-09-06 | JettStream, Inc. | Positionable elongated members with multi-axis joints |
WO2015149922A2 (en) * | 2014-03-31 | 2015-10-08 | Boehringer Ingelheim Vetmedica Gmbh | Inhaler |
US10751154B2 (en) * | 2014-03-31 | 2020-08-25 | Boehringer Ingelheim Vetmedica Gmbh | Inhaler |
DE102014011271A1 (en) * | 2014-07-29 | 2016-02-04 | Pari GmbH Spezialisten für effektive Inhalation | Ballast chamber with control element for inhaler |
US10737042B2 (en) * | 2014-08-26 | 2020-08-11 | Michael Edward Breede | Thermal modulation of an inhalable medicament |
US10300228B2 (en) * | 2014-08-26 | 2019-05-28 | Innovosciences, Llc | Thermal modulation of an inhalable medicament |
EP3220852A1 (en) | 2014-11-20 | 2017-09-27 | Boehringer Ingelheim Vetmedica GmbH | Container for an inhaler |
EP3095522A1 (en) * | 2015-05-20 | 2016-11-23 | Aptar Radolfzell GmbH | Inhalation device, inhalation device set and associated nozzle plate |
US10894142B2 (en) * | 2016-03-24 | 2021-01-19 | Trudell Medical International | Respiratory care system with electronic indicator |
CN105999505A (en) * | 2016-08-11 | 2016-10-12 | 张家港神港医疗用品有限公司 | Medical atomization oxygen mask |
FR3060398B1 (en) * | 2016-12-15 | 2019-07-19 | Aptar France Sas | NASAL DISTRIBUTION SET OF FLUID PRODUCT. |
CN112533656A (en) * | 2018-08-10 | 2021-03-19 | 索芙特海尔公司 | High pressure suction device |
CN113873903A (en) * | 2019-01-07 | 2021-12-31 | 弗里茨·施密特 | Method for qualitatively and/or quantitatively detecting substance contained in cannabis plant and kit used therein |
AU2022343639A1 (en) * | 2021-09-12 | 2024-03-28 | Niconox Llc | Delivery devices and compositions |
US20230364363A1 (en) * | 2022-05-16 | 2023-11-16 | Trudell Medical International | Aerosol delivery device with completed dosage indicator |
US11944742B1 (en) * | 2023-06-08 | 2024-04-02 | Microneb Tech Holdings, Inc. | Apparatus, methods, and systems for administering a medication to an animal |
CN117547694A (en) * | 2024-01-12 | 2024-02-13 | 橙心数字疗法(天津)有限公司 | Intelligent device for soft aerosol inhalation administration |
Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0537991A2 (en) * | 1991-10-15 | 1993-04-21 | Canadian Monaghan Limited | Equine mask |
WO1994017753A1 (en) | 1993-02-12 | 1994-08-18 | Minnesota Mining And Manufacturing Company | Aerosol delivery apparatus |
WO1996006011A2 (en) | 1994-08-11 | 1996-02-29 | Boehringer Ingelheim Kg | Closure cap and process for filling containers without forming gas bubbles |
CA2297174A1 (en) | 1997-08-04 | 1999-02-18 | Boehringer Ingelheim Pharma Kg | Aqueous aerosol preparations containing biologically active macromolecules and process for producing the corresponding aerosols |
US5964416A (en) * | 1995-10-04 | 1999-10-12 | Boehringer Ingelheim Gmbh | Device for producing high pressure in a fluid in miniature |
WO2000049988A2 (en) | 1999-02-23 | 2000-08-31 | Boehringer Ingelheim International Gmbh | Cartridge for a liquid |
WO2001035856A1 (en) * | 1999-11-16 | 2001-05-25 | Helle Funch Nielsen | Inhalator for treatment of bronchial disorder in horses |
WO2001078818A2 (en) | 2000-04-14 | 2001-10-25 | Trudell Medical International | Nasal inhaler |
US6401712B1 (en) * | 1996-04-25 | 2002-06-11 | Astrazeneca Ab | Inhaler |
WO2004091704A1 (en) | 2003-04-16 | 2004-10-28 | Trudell Medical International | Antistatic medication delivery apparatus |
US20040250816A1 (en) * | 2003-05-19 | 2004-12-16 | Pari Gmbh Spezialisten Fur Effective Inhalation | Inhalation therapy mask and device for animals |
WO2005079997A1 (en) | 2004-02-24 | 2005-09-01 | Boehringer Ingelheim International Gmbh | Atomiser |
EP1844805A1 (en) * | 2006-04-13 | 2007-10-17 | Boehringer Ingelheim Pharma GmbH & Co.KG | Inhaler |
WO2008067254A2 (en) * | 2006-11-27 | 2008-06-05 | Abbott Respiratory Llc | Nasal drug delivery device and method |
WO2009044172A1 (en) * | 2007-10-03 | 2009-04-09 | Optinose As | Nasal delivery devices |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5527527A (en) | 1989-09-07 | 1996-06-18 | Alkermes, Inc. | Transferrin receptor specific antibody-neuropharmaceutical agent conjugates |
EP0436155B1 (en) * | 1990-01-05 | 1994-08-24 | Maderag Ag | Extrusion gun for double-wall cartridges |
WO1993002729A1 (en) * | 1990-07-12 | 1993-02-18 | Habley Medical Technology Corporation | Super atomizing nonchlorinated fluorocarbon medication inhaler |
US5785049A (en) * | 1994-09-21 | 1998-07-28 | Inhale Therapeutic Systems | Method and apparatus for dispersion of dry powder medicaments |
AU697676B2 (en) * | 1994-09-21 | 1998-10-15 | Nektar Therapeutics | Apparatus and methods for dispersing dry powder medicaments |
US5695125A (en) * | 1995-02-09 | 1997-12-09 | Teknocraft, Inc. | Dual pressure regulator having balanced regulator valves supported in sprayer handle-conformal unibody structure |
TW469832U (en) | 1997-03-14 | 2001-12-21 | Astra Ab | Inhalation device |
JP3082728B2 (en) * | 1997-11-26 | 2000-08-28 | 西松 伸二 | Liquid spray device |
US6257233B1 (en) * | 1998-06-04 | 2001-07-10 | Inhale Therapeutic Systems | Dry powder dispersing apparatus and methods for their use |
GB0217199D0 (en) * | 2002-07-25 | 2002-09-04 | Glaxo Group Ltd | Medicament dispenser |
US7275534B2 (en) | 2003-01-31 | 2007-10-02 | Hewlett-Packard Development Company, L.P. | Medicament ejector with ejection port servicing |
US7458375B2 (en) * | 2006-09-01 | 2008-12-02 | Ai Medical Devices, Inc. | Endotracheal intubation device |
DE102005054383B4 (en) * | 2005-11-15 | 2013-10-31 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Needle for punching powder capsules for inhalation |
EP1795221A1 (en) * | 2005-12-02 | 2007-06-13 | Boehringer Ingelheim Pharma GmbH & Co. KG | Dispensing device, storage device and method for dispensing a formulation |
JP5047498B2 (en) * | 2005-12-28 | 2012-10-10 | 株式会社吉野工業所 | Two-component sprayer |
US7837656B2 (en) * | 2006-03-27 | 2010-11-23 | Tyco Healthcare Group Lp | Dual air regulated spray applicator |
DE102006023662A1 (en) * | 2006-05-18 | 2007-11-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | inhaler |
DE102006025871A1 (en) * | 2006-06-02 | 2007-12-06 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | atomizer |
-
2010
- 2010-06-14 WO PCT/EP2010/003522 patent/WO2010149280A1/en active Application Filing
- 2010-06-14 EP EP10727359.1A patent/EP2445558B1/en active Active
- 2010-06-14 KR KR1020117030937A patent/KR101641520B1/en active Search and Examination
- 2010-06-14 ES ES10727359.1T patent/ES2593428T3/en active Active
- 2010-06-14 CA CA2764469A patent/CA2764469C/en active Active
- 2010-06-14 US US13/322,249 patent/US9084660B2/en active Active
- 2010-06-14 MX MX2011013077A patent/MX2011013077A/en active IP Right Grant
- 2010-06-14 AU AU2010265187A patent/AU2010265187B2/en active Active
- 2010-06-14 JP JP2012516549A patent/JP2012530567A/en active Pending
- 2010-06-14 NZ NZ596456A patent/NZ596456A/en unknown
- 2010-06-14 DK DK10727359.1T patent/DK2445558T3/en active
- 2010-06-14 SG SG2011095320A patent/SG176961A1/en unknown
- 2010-06-14 BR BRPI1011813-6A patent/BRPI1011813B1/en active IP Right Grant
- 2010-06-14 CN CN2010800286530A patent/CN102458541A/en active Pending
- 2010-06-14 CN CN201510172911.7A patent/CN104799969B/en active Active
- 2010-06-25 TW TW099120928A patent/TWI526198B/en active
- 2010-06-25 AR ARP100102277A patent/AR077248A1/en active Pending
-
2011
- 2011-11-10 ZA ZA2011/08257A patent/ZA201108257B/en unknown
- 2011-12-23 CL CL2011003298A patent/CL2011003298A1/en unknown
- 2011-12-29 CO CO11181076A patent/CO6480981A2/en active IP Right Grant
-
2015
- 2015-06-09 JP JP2015116639A patent/JP6067784B2/en active Active
Patent Citations (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0537991A2 (en) * | 1991-10-15 | 1993-04-21 | Canadian Monaghan Limited | Equine mask |
WO1994017753A1 (en) | 1993-02-12 | 1994-08-18 | Minnesota Mining And Manufacturing Company | Aerosol delivery apparatus |
US5666948A (en) * | 1993-02-12 | 1997-09-16 | Minnesota Mining And Manufacturing Company | Attachment for aerosol device for large animals and method of use |
WO1996006011A2 (en) | 1994-08-11 | 1996-02-29 | Boehringer Ingelheim Kg | Closure cap and process for filling containers without forming gas bubbles |
US5964416A (en) * | 1995-10-04 | 1999-10-12 | Boehringer Ingelheim Gmbh | Device for producing high pressure in a fluid in miniature |
US6401712B1 (en) * | 1996-04-25 | 2002-06-11 | Astrazeneca Ab | Inhaler |
CA2297174A1 (en) | 1997-08-04 | 1999-02-18 | Boehringer Ingelheim Pharma Kg | Aqueous aerosol preparations containing biologically active macromolecules and process for producing the corresponding aerosols |
EP1003478A1 (en) | 1997-08-04 | 2000-05-31 | Boehringer Ingelheim Pharma KG | Aqueous aerosol preparations containing biologically active macromolecules and method for producing the corresponding aerosols |
WO2000049988A2 (en) | 1999-02-23 | 2000-08-31 | Boehringer Ingelheim International Gmbh | Cartridge for a liquid |
WO2001035856A1 (en) * | 1999-11-16 | 2001-05-25 | Helle Funch Nielsen | Inhalator for treatment of bronchial disorder in horses |
WO2001078818A2 (en) | 2000-04-14 | 2001-10-25 | Trudell Medical International | Nasal inhaler |
WO2004091704A1 (en) | 2003-04-16 | 2004-10-28 | Trudell Medical International | Antistatic medication delivery apparatus |
US20040250816A1 (en) * | 2003-05-19 | 2004-12-16 | Pari Gmbh Spezialisten Fur Effective Inhalation | Inhalation therapy mask and device for animals |
WO2005079997A1 (en) | 2004-02-24 | 2005-09-01 | Boehringer Ingelheim International Gmbh | Atomiser |
EP1844805A1 (en) * | 2006-04-13 | 2007-10-17 | Boehringer Ingelheim Pharma GmbH & Co.KG | Inhaler |
WO2008067254A2 (en) * | 2006-11-27 | 2008-06-05 | Abbott Respiratory Llc | Nasal drug delivery device and method |
WO2009044172A1 (en) * | 2007-10-03 | 2009-04-09 | Optinose As | Nasal delivery devices |
Cited By (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9179691B2 (en) | 2007-12-14 | 2015-11-10 | Aerodesigns, Inc. | Delivering aerosolizable food products |
US10124129B2 (en) | 2008-01-02 | 2018-11-13 | Boehringer Ingelheim International Gmbh | Dispensing device, storage device and method for dispensing a formulation |
US10124125B2 (en) | 2009-11-25 | 2018-11-13 | Boehringer Ingelheim International Gmbh | Nebulizer |
US10016568B2 (en) | 2009-11-25 | 2018-07-10 | Boehringer Ingelheim International Gmbh | Nebulizer |
US9943654B2 (en) | 2010-06-24 | 2018-04-17 | Boehringer Ingelheim International Gmbh | Nebulizer |
US20210196904A1 (en) * | 2012-03-09 | 2021-07-01 | Vectura Gmbh | Mixing channel for an inhalation device and inhalation device |
US10857310B2 (en) * | 2012-03-09 | 2020-12-08 | Vectura Gmbh | Mixing channel for an inhalation device and inhalation device |
US20150174343A1 (en) * | 2012-03-09 | 2015-06-25 | Vectura Gmbh | Mixing channel for an inhalation device and inhalation device |
US10220163B2 (en) | 2012-04-13 | 2019-03-05 | Boehringer Ingelheim International Gmbh | Nebuliser with coding means |
US10925964B2 (en) | 2012-12-21 | 2021-02-23 | Boehringer Ingelheim Vetmedica Gmbh | Pharmaceutical formulation comprising ciclesonide |
US10258634B2 (en) | 2012-12-21 | 2019-04-16 | Boehringer Ingelheim Vetmedica Gmbh | Ciclesonide for the treatment of airway disease in horses |
US11819549B2 (en) | 2012-12-21 | 2023-11-21 | Boehringer Ingelheim Vetmedica Gmbh | Pharmaceutical formulation comprising ciclesonide |
US9918995B2 (en) | 2012-12-21 | 2018-03-20 | Boehringer Ingelheim Vetmedica Gmbh | Ciclesonide for the treatment of airway disease in horses |
US10441597B2 (en) | 2012-12-21 | 2019-10-15 | Boehringer Ingelheim Vetmedica Gmbh | Ciclesonide for the treatment of airway disease in horses |
EP3257542A1 (en) * | 2013-08-09 | 2017-12-20 | Boehringer Ingelheim International GmbH | Nebulizer |
US11642476B2 (en) | 2013-08-09 | 2023-05-09 | Boehringer Ingelheim International Gmbh | Nebulizer |
US10004857B2 (en) | 2013-08-09 | 2018-06-26 | Boehringer Ingelheim International Gmbh | Nebulizer |
US10894134B2 (en) | 2013-08-09 | 2021-01-19 | Boehringer Ingelheim International Gmbh | Nebulizer |
WO2015024653A1 (en) | 2013-08-20 | 2015-02-26 | Boehringer Ingelheim Vetmedica Gmbh | Inhaler |
DE202014006619U1 (en) | 2013-08-20 | 2014-11-24 | Boehringer Ingelheim Vetmedica Gmbh | inhaler |
WO2015024651A1 (en) | 2013-08-20 | 2015-02-26 | Boehringer Ingelheim Vetmedica Gmbh | Inhaler |
EP4257171A2 (en) | 2013-08-20 | 2023-10-11 | Boehringer Ingelheim Vetmedica GmbH | Inhaler |
EP4295880A2 (en) | 2013-08-20 | 2023-12-27 | Boehringer Ingelheim Vetmedica GmbH | Inhaler |
DE202014006617U1 (en) | 2013-08-20 | 2014-11-24 | Boehringer Ingelheim Vetmedica Gmbh | inhaler |
WO2015024652A1 (en) | 2013-08-20 | 2015-02-26 | Boehringer Ingelheim Vetmedica Gmbh | Inhaler |
DE202014006618U1 (en) | 2013-08-20 | 2014-11-24 | Boehringer Ingelheim Vetmedica Gmbh | inhaler |
EP3766456A1 (en) | 2013-08-20 | 2021-01-20 | Boehringer Ingelheim Vetmedica GmbH | Inhaler |
EP3632372A1 (en) | 2013-08-20 | 2020-04-08 | Boehringer Ingelheim Vetmedica GmbH | Inhaler |
EP3632373A1 (en) | 2013-08-20 | 2020-04-08 | Boehringer Ingelheim Vetmedica GmbH | Inhaler |
CN104001248A (en) * | 2014-06-11 | 2014-08-27 | 邵俊夫 | Essential oil smelling apparatus |
AU2020202402B2 (en) * | 2014-06-18 | 2021-05-27 | Boehringer Ingelheim Vetmedica Gmbh | Muscarinic antagonists and combinations thereof for the treatment of airway disease in horses |
US9474747B2 (en) | 2014-06-18 | 2016-10-25 | Boehringer Ingelheim Vetmedica Gmbh | Muscarinic antagonists and combinations thereof for the treatment of airway disease in horses |
EP3603640A1 (en) | 2014-06-18 | 2020-02-05 | Boehringer Ingelheim Vetmedica GmbH | Muscarinic antagonists and combinations thereof for the treatment of airway disease in horses |
WO2015193213A1 (en) * | 2014-06-18 | 2015-12-23 | Boehringer Ingelheim Vetmedica Gmbh | Muscarinic antagonists and combinations thereof for the treatment of airway disease in horses |
AU2015276310B2 (en) * | 2014-06-18 | 2020-01-16 | Boehringer Ingelheim Vetmedica Gmbh | Muscarinic antagonists and combinations thereof for the treatment of airway disease in horses |
US10342789B2 (en) | 2014-06-18 | 2019-07-09 | Boehringer Ingelheim Vetmedica Gmbh | Muscarinic antagonists and combinations thereof for the treatment of airway disease in horses |
FR3054135A1 (en) * | 2016-07-22 | 2018-01-26 | La Diffusion Technique Francaise | INHALATION DEVICE, TREATMENT SYSTEM, AND METHOD FOR IMPLEMENTING THE SAME |
EP3272381A1 (en) * | 2016-07-22 | 2018-01-24 | La Diffusion Technique Francaise | Inhaler device and treatment system |
WO2019125304A1 (en) * | 2017-12-18 | 2019-06-27 | National University Of Singapore | Spacer device for an inhaler and method of manufacture thereof |
WO2019178693A1 (en) * | 2018-03-21 | 2019-09-26 | Protecsom Amerique Du Nord Inc. | Nasal cannula for an aerosol reservoir such as an inhalation chamber |
EP4124251A4 (en) * | 2021-06-08 | 2023-10-25 | KT&G Corporation | Aerosol generation device |
Also Published As
Publication number | Publication date |
---|---|
EP2445558A1 (en) | 2012-05-02 |
BRPI1011813B1 (en) | 2020-08-04 |
JP6067784B2 (en) | 2017-01-25 |
AR077248A1 (en) | 2011-08-10 |
CO6480981A2 (en) | 2012-07-16 |
US9084660B2 (en) | 2015-07-21 |
AU2010265187B2 (en) | 2015-05-14 |
KR101641520B1 (en) | 2016-07-21 |
ES2593428T3 (en) | 2016-12-09 |
AU2010265187A1 (en) | 2011-12-08 |
TWI526198B (en) | 2016-03-21 |
NZ596456A (en) | 2014-01-31 |
CA2764469A1 (en) | 2010-12-29 |
CN104799969A (en) | 2015-07-29 |
US20120103326A1 (en) | 2012-05-03 |
SG176961A1 (en) | 2012-02-28 |
BRPI1011813A2 (en) | 2016-03-29 |
JP2015157178A (en) | 2015-09-03 |
EP2445558B1 (en) | 2016-06-29 |
MX2011013077A (en) | 2012-01-20 |
CA2764469C (en) | 2017-10-03 |
DK2445558T3 (en) | 2016-09-19 |
KR20120098404A (en) | 2012-09-05 |
CN104799969B (en) | 2018-11-06 |
JP2012530567A (en) | 2012-12-06 |
TW201103504A (en) | 2011-02-01 |
CN102458541A (en) | 2012-05-16 |
ZA201108257B (en) | 2012-08-29 |
CL2011003298A1 (en) | 2012-05-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2445558B1 (en) | Inhaler | |
US9682202B2 (en) | Adapter, inhalation device, and atomizer | |
EP2326374B1 (en) | Inhaler | |
CA2653422A1 (en) | Atomizer | |
CA2650181A1 (en) | Atomiser | |
EP2676694B1 (en) | Inhaler | |
US9108011B2 (en) | Inhalation device |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201080028653.0 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10727359 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010727359 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010265187 Country of ref document: AU Ref document number: 596456 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2764469 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2011/013077 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 2010265187 Country of ref document: AU Date of ref document: 20100614 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012516549 Country of ref document: JP |
|
ENP | Entry into the national phase |
Ref document number: 20117030937 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10187/DELNP/2011 Country of ref document: IN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11181076 Country of ref document: CO |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13322249 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: PI1011813 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: PI1011813 Country of ref document: BR Kind code of ref document: A2 Effective date: 20111223 |